A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 20, Issue 1, 1996, Pages 57-71

  Dierick, Michel ^a,d   Ravizza, Luigi ^b   Realini, Renzo ^e   Martin, Alain ^c  

^a St Camillus Psychiatric Hospital   (Belgium)

^b UNIVERSITY OF TURIN   (Italy)

^c Centre Hospitalier de Beaumont Oise   (France)

^d Sint Camillus Psychiatric Hospital   (Belgium)

^e NONE

Author keywords

fluoxetine; major depression; venlafaxine

Indexed keywords

FLUOXETINE; VENLAFAXINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTPATIENT; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 0029871802     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/0278-5846(95)00292-8     Document Type: Article

References (24)

1. ALTAMURA, A.C., MONTGOMERY, S.A. and WERNICKE, J.F. (1988) The Evidence For 20 Mg a Day of Fluoxetine as The Optimal Dose in the Treatment of Depression. Br. J. Psychiatry 153 (suppl 3): 109-112.
2. BEASLEY, C.M. Jr., BOSOMWORTH, J.C. and WERNICKE, J.F. (1990) Fluoxetine: Relationships Among Dose, Response, Adverse Events, and Plasma Concentrations in the Treatment of Depression. Psychopharmacol. Bull. 26: 18-24.
3. BENKERT, O., HACKETT, D., REALINI, R., WHITE, C. and DE WILDE, J. (1994) A Randomised, Double-Blind Comparison of a Rapidly Escalating Dose of Venlafaxine and Imipramine in Inpatients with Major Depression and Melancholia (Abstract). Neuropsychopharmacology. 10 (suppl): 165 S.
4. BOLDEN-WATSON, C. and RICHELSON, E. (1993) Blockade By Newly-Developed Antidepressants Of Biogenic Amine Uptake Into Rat Brain Synaptosomes. Life Sciences 52: 1023-1029.
5. CLERC, G.E., RUIMY, P. and VERDEAU-PAILLES, J. (1994) A Double-Blind Comparison of Venlafaxine and Fluoxetine in Patients Hospitalized for Major Depression and Melancholia. Int. Clin. Psychopharmacol. 9: 138-143.
6. CUNNINGHAM, L.A., BORISON, R.L., CARMAN, J.S., CHOUINARD, G., CROWDER, J.E., DIAMOND, B.I., FISCHER, D.E. and HEARST, E. (1994) A Comparison of Venlafaxine, Trazodone, and Placebo in Major Depression. J. Clin. Psychopharmacol. 14: 99-106.
7. DORNSEIF BE, DUNLOP SR, POTVIN JH WERNICKE JF. (1989) Effect Of Dose Escalation After Low-Dose Fluoxetine Therapy. Psychopharmacol. Bull. 25: 71-79.
8. FAVA, M., RAPPE, S.M., PAVA, J.A., NIERENBERG, A.A., ALPERT, J.E. AND ROSENBAUM, J.F. (1995) Relapse In Patients On Long-Term Fluoxetine Treatment: Response To Increased Fluoxetine Dose. J. Clin. Psychiatry 56: 52-55.
9. GOLDBERG, H.L. and FINNERTY, R. (1988) An Open-Label, Variable-Dose Study Of Wy45,030 (Venlafaxine) In Depressed Outpatients. Psychopharmacol. Bull. 24: 198-199.
10. GRAM, L.F. (1994) Fluoxetine. N. Engl. J. Med. 331: 1354-1361.
11. GUELFI, J.D., WHITE, C., HACKETT D, GUICHOUX, J.Y. and MAGNI, G. (1995) Effectiveness Of Venlafaxine In Patients Hospitalized With Major Depression And Melancholia. J. Clin. Psychiatry 56:
12. GUY, W. (1976) ECDEU Assessment Manual For Psychopharmacology, Revised. DHEW Pub. No. (ADM)76-338, National Institutes of Mental Health, Rockville, MD.
13. HAMILTON, M.A. (1960) A Rating Scale For Depression. J. Neurol. Neurosurg. Psychiatry 23: 56-62.
14. KHAN, A., FABRE, L.F., and RUDOLPH, R. (1991) Venlafaxine in Depressed Outpatients. Psychopharmacol. Bull. 27: 141-144.
15. MENDELS, J., JOHNSTON, R., MATTES, J., and RIESENBERG, R. (1993) Efficacy and Safety of B.I.D. Doses of Venlafaxine in a Dose-Response Study. Psychopharm. Bull. 29: 169-174.
16. MONTGOMERY, S.A., and ASBERG, M. (1979) A New Depression Scale Designed to be Sensitive to Change. Br. J. Psychiatry 134: 382-389.
17. MUTH, E.A., HASKINS, J.T., MOYER, J.A., HUSBANDS, G.E., NIELSEN, ST., and SIGG, S.B. (1986) Antidepressant Biochemical Profile of the Novel Bicyclic Compound Wy-45,030, An Ethyl Cyclohexanol Derivative. Biochem. Pharmacol. 35: 4493-4497.
18. PRESKORN, S.H. (1993) Pharmacokinetics Of Psychotropic Agents: Why And How They Are Relevant To Treatment. J. Clin. Psychiatry 54(suppl 9): 14-34.
19. RUDOLPH, R., ENTSUAH, R., and DERIVAN, A. (1991) Early Clinical Response in Depression to Venlafaxine Hydrochloride (Abstract). Biol. Psychiatry 29: 630S.
20. SCHWEIZER, E., CLARY, C., WEISE, C., and RICKELS, K. (1988) An Open-Label, Dose-Finding Study of Wy-45,030, a Novel Bicyclic Antidepressant. Psychopharmacol. Bull. 24: 195-197.
21. SCHWEIZER, E., AMSTERDAM, J., WEISE, C. and RICKELS, K. (1990) What Constitutes an Adequate Antidepressant Trial for Fluoxetine? J. Clin. Psychiatry 51: 8-11.
22. SCHWEIZER, E., WEISE, C., CLARY, C., FOX, L., and RICKELS, K. (1991) Placebo-Controlled Trial of Venlafaxine for the Treatment of Major Depression. J. Clin. Psychopharmacol. 11: 233-236.
23. SCHWEIZER, E., FEIGHNER, J., MANDOS, L., and RICKELS, K. (1994) Comparison of Venlafaxine and Imipramine in the Acute Treatment of Major Depression in Outpatients. J. Clin. Psychiatry 55: 104-108.
24. SHRIVASTAVA, R., COHN, C., CROWDER, J., DAVIDSON, J., DUNNER, D., FEIGHNER, J., KIEV, A., and PATRICK, R. (1994) Long-Term Safety and Clinical Acceptability of Venlafaxine and lmipramine in Outpatients with Major Depression. J. Clin. Psychopharmacol. 14: 322-329.